Tyverb is indicated in combination with capecitabine for advanced or metastatic breast cancer in patients whose tumours overexpress ErbB2 (HER2). Patients should have progressive disease following prior therapy that included anthracyclines and taxanes and trastuzumab in the metastatic setting.
Lapatinib has a 'conditional licence' which is valid for 1 year and requires GSK to provide further trial data. A conditional licence is granted when a drug fulfils an unmet medical need and the benefit to public health outweighs the risk that additional data are still required.
Further information: GlaxoSmithKline